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Objectives: Asbestos induces generation of reactive oxygen and nitrogen species in laboratory
studies. Several such species can be measured non-invasively in humans in exhaled breath
condensate (EBC) but few have been evaluated. This study aimed to assess oxidative stress
and lung inflammation in vivo.
Methods: Eighty six men were studied: sixty subjects with asbestos-related disorders (asbes-
tosis: 18, diffuse pleural thickening (DPT): 16, pleural plaques (PPs): 26) and twenty six age-
and gender-matched normal individuals.
Results: Subjects with asbestosis had raised EBC markers of oxidative stress compared
with normal controls [8-isoprostane (geometric mean (95% CI) 0.51 (0.17e1.51) vs 0.07
(0.04e0.13) ng/ml, p< 0.01); hydrogen peroxide (13.68 (8.63e21.68) vs 5.89 (3.99e8.69)
mM, p < 0.05), as well as increased EBC total protein (17.27 (10.57e28.23) vs 7.62
(5.13e11.34) mg/ml, p< 0.05), and fractional exhaled nitric oxide (mean SD) (9.67 3.26
vs 7.57 1.89 ppb; p< 0.05). EBC pH was lower in subjects with asbestosis compared with
subjects with DPT (7.26 0.31 vs 7.53 0.24; p< 0.05). There were no significant differences
in exhaled carbon monoxide, EBC total nitrogen oxides and 3-nitrotyrosine between any of the
asbestos-related disorders, or between these and controls.
Conclusion: In asbestos-related disorders, markers of inflammation and oxidative stress are
significantly elevated in subjects with asbestosis compared with healthy individuals but not
in pleural diseases.
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Lung disease due to inhalation of asbestos fibres continues to
be a significant problem worldwide.1e4 Several different
diseases occur,5 including asbestosis (diffuse interstitial
pulmonary fibrosis due to asbestos inhalation) and pleural
plaques (PPs). PPs are the commonest asbestos-related
abnormality and generally regarded as benign markers of
asbestos exposure. In contrast, diffuse pleural thickening
(DPT) is rarer and results in a restrictive ventilatorydefect and
significant symptoms even in the absence of asbestosis.6 Dis-
tinguishing between asbestosis and asbestos-related pleural
disorders is important not only for overall disease prognosis
but also because of the acknowledged link betweenasbestosis
and DPTand the development of lung cancer. The risk of lung
cancer with asbestos exposure in the absence of asbestosis is
significantly lower, although still under active debate.
Asbestos induces inflammation and cell death in animal
models, modulating cell proliferation and causing DNA
damage. It activates lung inflammatory cells such as
neutrophils and macrophages, generating reactive metab-
olites such as hydrogen peroxide, superoxide anions,
hydroxyl radicals and nitric oxide.7 Traditional methods of
assessing lung inflammation (such as bronchoalveolar
lavage (BAL), biopsy) in asbestos-related disorders are
hampered by the fact that these are invasive, and patients
affected are usually elderly, with poor lung function and
frequent concurrent disease. Simple, non-invasive tests
which accurately reflect lung pathology would therefore be
of considerable use in diagnosis and possibly also in moni-
toring progress of these disorders.
Recently, several novel non-invasive techniques to assess
lung disease have been developed. Exhaled breath consists
of a gaseous phase containing volatile mediators (e.g. NO,
CO) and a liquid phase which can be collected as exhaled
breath condensate (EBC). Fractional exhaled nitric oxide
(FeNO) has been measured in many lung diseases8,9 and is
raised in asbestosis10,11 as well as in asthma8 and pulmonary
fibrosis.12 However, it is non-specific. A more specific
pattern of biomarkers might emerge using additional non-
invasive techniques, in addition to elucidating underlying
disease mechanisms. EBC could prove helpful in this regard.
Inflammatory markers as well as those of oxidative imbal-
ance can be measured in EBC and an increasing number of
EBC biomarkers are being described. American Thoracic
Society (ATS) and the European Respiratory Society (ERS)
have recently published recommendations which summarise
knowledge in this area.13 EBC is minimally invasive, easy for
the patient, and can be repeated frequently. However,
much still remains to be learnt about this new area.14,15
In this study, we aimed to assess lung oxidative stress and
inflammation in vivo in subjects with asbestos-related
disorders and compare them with age matched controls.
Although a limited number of EBC biomarkers have been
examined in asbestosis in one report to date, there have
been no studies examining subjects with other asbestos-
related lung disorders. We hypothesized that, similar to
animal and in vitro studies,16,17 markers of oxidative stress
and those of lung inflammation would be elevated in
asbestosis compared with controls but to a lesser extent in
subjects with asbestos-related pleural disorders.Methods
Study subjects
Subjects were recruited from the Dust Diseases Board (DDB)
of New South Wales, and from St Vincent’s Hospital,
Sydney. The study was approved by the Human Research
Ethics Committee (HREC) and informed consent was
obtained from all participants.
All subjects had a confirmed history of workplace
asbestos exposure other than controls and were classified
into three groups (asbestosis, diffuse pleural thickening
(DPT) and pleural plaques (PPs)) according to current ATS
recommendations.5 Smokers were excluded, but ex-
smokers (who had stopped smoking 1 year) were included
provided there was no evidence of other lung diseases. Age
and sex-matched controls were recruited from St Vincent’s
Hospital and the DDB. All control subjects were never or ex-
smokers without any evidence of asbestos-related or other
lung disease after screening. Subjects with asthma, COPD
or any other factors which were likely to affect EBC or FeNO
(e.g. inhaled glucocorticosteroids, nitrates) were excluded
from the study.
Pulmonary function testing
All subjects had lung function performed according to ATS/
ERS guidelines18 on the same day of the EBC collection.
Forced expiratory volume in 1 s (FEV1 (L)), forced vital
capacity (FVC (L)), vital capacity (VC (L)) and diffusing
capacity for carbon monoxide (DLCO (ml/mmHg/min))
were measured via spirometry or body plethysmography
(Vmax Spectra 22D, SensorMedics, CA, USA). Percentage of
predicted values (% pred) was calculated using the Euro-
pean Coal and Steel regression equations.19
Exhaled breath condensate biomarkers and
exhaled breath markers
EBC was collected using a dedicated breath refrigeration
circuit Ecoscreen (Erich Jaeger GmbH, Hochberg,
Germany) according to ERS/ATS recommendations.13
Subjects first rinsed their mouths with distilled water and
breathed tidally through a mouthpiece connected to
a two-way non-rebreathing valve with nose-clip on, con-
taining a saliva trap. One to two millilitres of condensate
was collected after 10 min. In order to minimize thawe
freeze cycles and stabilize EBC biomarkers, the cooled
condensate was immediately separated in aliquots and
stored at 80 C for further assays within 3 months. Enz-
Chek Ultra Amylase kit (Molecular Probes, Invitrogen,
Oregon, USA) was used to test the presence of a-amylase
in samples (sensitivity: down to 2 mU/ml). Saliva
contaminated EBC samples were excluded. FeNO and
exhaled CO were measured online according to ERS and
ATS specifications,9 using a rapid-response chem-
iluminescence NO and CO analyzer (LR 2500 (I); Logan
Research, Rochester, UK). A constant expiratory flow rate
of 250 ml/min was used, which was chosen to more closely
reflect alveolar NO flux.11
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Total nitrogen oxides (NOx) were measured after enzymatic
reduction of nitrate using a fluorimetric modification of the
Greiss reaction.14,20 Lower limit of detection of this assay was
2 mM. Total protein concentration was measured using
a Quantipro BCA assay kit (SigmaeAldrich, Sydney, Australia),
with lower limit of detection at 4 mg/ml. 8-Isoprostane was
measured using a specific enzyme-immunoassay (EIA) kit
(Cayman Chemical, Ann Arbor, MI, USA), validated to obtain
a high correlation (0.95) with known amounts of 8-iso-
prostane and with lower detection limit 5 pg/ml.21 Hydrogen
peroxide (H2O2) was measured spectrophotometrically by
horseradish peroxidase-catalysed oxidation of tetrame-
thylbenzidine.13,14 The nitration product of tyrosine,
3-nitrotyrosine, wasmeasured via enzyme immunoassay (EIA)
(Cayman Chemical, Ann Arbor, MI, USA). Lower limit of
detection was 4 ng/ml. EBC acidity was measured immedi-
ately after defrosting frozen EBC samples with a pH sensor
probe (IQ125 MiniLab Professional pH meter, Merck, CA,
USA). pH measurement range was 2e12 (0.1 pH).
Statistical analysis
Where data did not conform to Normal distribution, these
were log transformed. Data were expressed as means
standard deviation (SD) and as geometric means (95%
confidence intervals (CI)) when log transformed unless
otherwise stated. Sample size was calculated based on pH
values from previously published data.22 One way analysis
of variance (ANOVA) and a multiple comparison post hoc
tests were used for comparison between groups. Results
were considered significant if p< 0.05. Correlation
between biomarkers and lung function parameters was
performed using Pearson’s correlation coefficient.
Results
Subjects
Eighty-six male subjects were studied (48 ex-smokers and
38 never smokers). None of the subjects was using inhaled
corticosteroids. Demographic data are shown in Table 1.Table 1 Demographic data of study subjects and lung function
Subject characteristics Normal Pleural
No. of patients 26 26
Age (years) 71 9.19 70
Ex-smokers 12 (46%) 11 (42%
Lung function results
FEV1 (%pred) 91.65 15.41 89.12
FVC (%pred) 91.88 16.46 91.73
VC (%pred) 98.18 15.80 100.0
DLCO (%pred) 89.43 15.26 86.69
Data presented as means standard deviations unless otherwise spec
Significant difference between subjects with asbestosis and DPT and n
with asbestosis and those with pleural plaques (#p< 0.001).FEV1, FVC, VC and DLCO were reduced in subjects with
asbestosis and differed significantly from normal subjects
(p< 0.05). Subjects with asbestosis had significantly
reduced DLCO (% pred) compared to controls and PPs
(56.94% 20.87 vs 89.43% 15.26; 86.69% 16.06%;
p< 0.001 respectively), while those with DPT had signifi-
cantly decreased FEV1 and DLCO but FVC and VC did not
differ from other groups.
EBC markers of oxidative stress: 8-isoprostane and
hydrogen peroxide
EBC 8-isoprostane in patients with asbestosis was signifi-
cantly increased compared to normal subjects (geometric
mean (95%CI) 0.51 (0.17e1.51) vs 0.07 (0.04e0.13) ng/ml,
p< 0.01; Fig. 1A). EBC 8-isoprostane directly correlated
with EBC total protein (rZ 0.33, pZ 0.003), NOx (rZ 0.59,
p< 0.0001) and H2O2 (rZ 0.76, p< 0.0001).
EBC H2O2 was also increased in patients with asbestosis
compared to normal controls (13.68 (8.63e21.68) vs 5.89
(3.99e8.69) mM, p< 0.05; Fig. 1B). A trend towards
increasing H2O2 levels with increasing severity of lung
disease was observed. H2O2 levels were also significantly
correlated with exhaled NOx (rZ 0.61, p< 0.0001) and
protein (rZ 0.74, p< 0.0001).
EBC total protein concentration in subjects with asbes-
tosis was also significantly increased compared to control
subjects (17.27 (10.57e28.23) vs 7.62 (5.13e11.34) mg/ml,
p< 0.05; Fig. 2A). A trend towards higher protein levels in
subjects with DPTwas observed but did not reach statistical
significance. There was no significant correlation between
EBC protein and lung function, nor with FeNO or eCO in any
group. EBC protein levels directly correlated with NOx
(rZ 0.50, p< 0.0001), 8-isoprostane and hydrogen
peroxide as above.
EBC nitrogen oxides (NOx) and 3-nitrotyrosine
EBC NOx was measurable in all groups. A trend towards
increasing EBC NOx concentrations in patients with DPT and
asbestosis compared with normal controls was observed but
did not reach statistical significance. EBC levels of NOx did
not correlate with 3-nitrotyrosine or hydrogen ion (Hþ)
concentration in EBC. However, NOx correlated directlyresults.
plaques DPT Asbestosis
16 18
5.23 72 7.04 75 5.58
) 11 (69%) 14 (78%)
16.41 78.31 19.68* 78.47 26.3*
16.04 82.88 18.47 77.71 20.11*
10.98 87.00 17.91 3.23 24.24*
16.06 75.31 22.13* 56.94 20.87***,#
ified.
ormal controls (***p< 0.001, *p< 0.05) and also between subjects
Figure 1 Exhaled breath condensate (EBC) biomarkers in subjects with different asbestos-related disorders compared with
normal individuals. Levels of (A) 8-isoprostane, ng/ml in EBC in normal controls (nZ 25), pleural plaques (PPs) (nZ 24), diffuse
pleural thickening (DPT) (nZ 14) and asbestosis (nZ 17). (B) hydrogen peroxide (H2O2), mM in EBC in normal controls (nZ 25), PPs
(nZ 26), DPT (nZ 16) and asbestosis (nZ 18). (BarsZ geometric means.)
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(rZ 0.59, p< 0.0001) and H2O2 (rZ 0.61, p< 0.0001) in
EBC in all groups.
3-Nitrotyrosine was difficult to detect in EBC of normal
subjects. Most of the results were close to the limit of
detection of the assay and below this in 20 patients.
However, there was no significant difference in EBC
3-nitrotyrosine between normal subjects and patients with
asbestos-related diseases, and no significant correlation
between 3-nitrotyrosine and either FeNO levels, other EBC
biomarkers or lung function.
EBC pH (HD concentration)
Subjects with asbestosis had significantly lower EBC pH than
individuals with DPT (7.26 0.31 versus 7.53 0.24,
p< 0.05; Fig. 2B). EBC pH was lower in asbestosis than in
controls but this did not reach statistical significance
(7.26 0.31 versus 7.44 0.32, pZ 0.07). There were no
significant EBC pH differences between other groups. No
significant correlation between Hþ and other biomarkers or
lung function was observed.Figure 2 Exhaled breath condensate (EBC) biomarkers in subje
normal individuals. Levels of (A) total protein, mg/ml in EBC in norm
(nZ 17). (BarsZ geometric means.) (B) EBC pH in normal subject
(BarsZmeans.)Exhaled breath markers: fractional exhaled nitric
oxide (FeNO) and exhaled carbon monoxide (eCO)
FeNO was significantly increased in patients with asbestosis
compared with controls (9.67 3.26 versus 7.57 1.89 ppb;
p< 0.05) (Table 2, Fig. 3). There was no significant
correlation between FeNO and lung function, or with
any EBC biomarker. There was no significant difference
in eCO between the different asbestos-related diseases
nor compared with controls, neither any significant
correlation between eCO and lung function or EBC
biomarkers.
Discussion
Non-invasive techniques have not yet been widely investi-
gated in occupational lung disease. These methods are
totally non-invasive, inexpensive and easy to repeat,
providing a rapid method of assessing biomarker levels.
FeNO has evolved over the last decade from a research tool
into a clinical measurement useful for diagnosing andcts with different asbestos-related disorders compared with
al controls (nZ 24), PPs (nZ 25), DPT (nZ 16) and asbestosis
s (nZ 26), PPs (nZ 25), DPT (nZ 16) and asbestosis (nZ 17).
Table 2 Exhaled breath condensate (EBC) biomarker levels.
EBC biomarkers Normal Pleural plaques DPT Asbestosis
eCO (ppm) 2.55 0.96 2.60 0.85 2.80 0.81 1.82 1.06
NOx (mm) 28.72 17.11 28.54 17.97 36.68 24.51 35.94 22.74
3-Nitrotyrosine (ng/ml) 0.39 (0.13e1.18) 1.47 (0.60e3.61) 2.23 (0.45e11.18) 0.20 (0.05e0.86)
FeNO (ppb) 7.57 1.89 8.38 3.43 8.92 4.08 9.67 3.26*
pH 7.44 0.32 7.40 0.37 7.53 0.24 7.26 0.30y
Hþ ions (mm) 0.05 0.04 0.08 0.19 0.03 0.02 0.07 0.06y
Protein (mg/ml) 7.62 (5.13e11.34) 8.05 (5.27e12.29) 12.94 (9.00e18.59) 17.27 (10.57e28.23)*
8-isoprostane (ng/ml) 0.07 (0.04e0.13) 0.12 (0.06e0.23) 0.22 (0.07e0.71) 0.51 (0.17e1.151)**
H2O2 (mm) 5.89 (3.99e8.69) 6.96 (5.03e9.63) 9.16 (6.24e13.44) 13.68 (8.63e21.68)*
Data presented as means standard deviation and those log transformed expressed as geometric means (95% confidence interval);
significant difference between subjects with asbestosis and normal controls (**p< 0.01; *p< 0.05) and also between those with
asbestosis and DPT (yp< 0.05).
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occupational asthma.23
Much less information is available about EBC biomarker
analysis, particularly with regard to asbestos-related
disorders, with only two reports to date published on this
topic.11,24 Our results confirm our own previous findings
that FeNO is raised in asbestosis10 and are compatible with
that of others11,25,26 as well as revealing new information
regarding EBC biomarkers in the range of asbestos-related
disorders. We have confirmed laboratory evidence sug-
gesting that reactive oxygen species (ROS) and reactive
nitrogen species (RNS) play an important role in inducing
lung toxicity from asbestos7,27 in vivo, and that levels of
oxidative stress differ between the different asbestos-
related disorders. Although our study was not designed
specifically to compare conventional methods with newer
techniques, it seems likely that non-invasive methods may
prove a useful addition to these in the future, particularly
in elderly or infirm patients.
Asbestos fibres are cytotoxic both in vitro and in vivo.7,17
Asbestos produces ROS (superoxide, H2O2 and hydroxyl
radicals) and RNS (nitric oxide, nitrogen oxides and perox-
ynitrite) by at least two mechanisms.28 ROS contributeFigure 3 Fractional exhaled nitric oxide (FeNO) measured in
parts per billion (ppb) in normal subjects (nZ 19), PPs (nZ 17),
DPT (nZ 12) and asbestosis (nZ 16). (BarsZmeans.)towards asbestos-induced alveolar cell injury through lipid
peroxidation and release of inflammatory cytokines,
leading to apoptosis, persistent lung inflammation and
potentially also to malignant transformation. A variety of
different cytokines are probably involved, including TNF
isoforms,29 macrophage inflammatory protein 2 (MIP-2),
PDGF isoforms30 and also interleukins such as IL-1 and
IL-8.28 Although the current study did not examine the full
range of such cytokines, several of these have been
measured in EBC in our laboratory,10,14 and this study has
confirmed the feasibility of their measurement in future
research into asbestos-related disorders.
Information is still evolving about technical aspects of
EBC, its clinical application, and its potential confounding
factors.13,15 A wide variety of different biomarkers can be
measured,14,31 and lung acidification assessed,32 but the
exact origin of EBC and all the factors affecting biomarker
concentrations have yet to be fully elucidated. While
acknowledging this, we carefully designed our study to
exclude known factors such as smoking33,34 and inhaled
corticosteroids35,36 that affect EBC biomarker levels,
utilized age and sex-matched controls, and collected and
analyzed our samples according to published recommen-
dations.13 One potential confounding factor is the fact that
our subjects (although current non-smokers and age- and
sex-matched) were not matched for past smoking habit.
However, we believe this to be unlikely as an explanation of
our results, as we excluded all subjects with a past medical
history of asthma or emphysema, and none had airflow
obstruction on lung function testing. Also, the proportion of
ex-smokers in our group with DPT was similar to that in our
group with asbestosis; yet significant differences in
biomarkers were found only in the latter.
Several studies37,38 have shown poor reproducibility of
biomarkers in EBC, although pH is probably more repro-
ducible,33,39,40 and there is still on-going debate regarding
potential salivary contamination for NOx in particular.
However, this is less relevant to our study because we used
identical techniques for subjects with disease and controls,
so any error should apply equally to both techniques, and
we included an adequate number of subjects. We used the
EcoScreen commercial device for EBC sampling which
collects EBC as ice, which is thought to be beneficial for
unstable markers, and the methodology recommended by
the ATS/ERS task force.13 We did not de-aerate EBC with
1096 S. Chow et al.argon gas prior to pH measurement because our study was
initiated before this was recommended, when opinion
regarding the advisability of this procedure was divided.
However, our results are consistent with our previous data14
which showed a close correlation between aerated and de-
aerated samples, and were not the primary outcome vari-
able of the study.
The elevated FeNO we once again found in asbestosis is
likely to reflect on-going lower respiratory tract inflam-
mation and is probably alveolar in origin. We did not have
the facility for extended NO measurement, but Lehtonen
and colleagues,11 have studied this and found that alveolar
NO concentrations were raised in asbestosis compared with
healthy controls whereas bronchial NO flux was similar in
both groups.11 Exhaled CO, which has been variably shown
to be increased in asthma41 did not differ among the groups
in our study. We also found markers of oxidative stress
(8-isoprostane and hydrogen peroxide) to be elevated in
subjects with asbestosis but not other asbestos-related lung
disorders. 8-Isoprostane is a stable end product of lipid
peroxidation which is released from inflammatory cells
activated by asbestos fibres.28 H2O2 is produced by several
inflammatory cells including pulmonary macrophages and
by parenchymal epithelial cells.17,28 8-Isoprostane has been
reported to be increased in EBC of patients with different
respiratory diseases,11,21,42 including in asbestosis.11,25 Our
findings confirm these findings and extend them to include
H2O2, where elevated H2O2 levels were similar to subjects
with idiopathic pulmonary fibrosis.42
We assessed EBC total nitrogen oxides (NOx) and
3-nitrotyrosine. 3-Nitrotyrosine is an end product formed
upon reaction of free or protein-bound tyrosine with NOx.
Unlike FeNO, EBC 3-nitrotyrosine and NOx were not signif-
icantly increased in the asbestos-exposed group compared
to controls, nor did these correlate with FeNO. However,
EBC NOx did show some non-significant trend towards
a relationship with increased lung inflammation, with
a gradation in levels from the PPs to the asbestosis groups.
EBC NOx are in general unstable and have been well
documented to be affected by several other factors e.g.
oral bacteria, diet, NOx contamination from the collection
device.39,43 3-Nitrotyrosine proved difficult to measure and
did not add to our findings. Overall, our results indicate
that NOx and 3-nitrotyrosine are currently not useful for
assessing asbestos-related disease.
The stability and bioactivities of many RNS and ROS are
pH dependent, and thus airway pH is likely to be relevant
to the effects of asbestos on the lung. Airway pH changes
in a variety of different lung diseases including asthma,32
COPD44 and also with gastro-oesophageal reflux,45 but has
not been previously assessed in asbestos related
disorders. We found that subjects with asbestosis had
a significantly lower EBC pH than individuals with DPT, but
no differences were observed between other groups. We
did not find any correlation between FeNO and pH nor
NOx levels, similar to our previous findings,14 and that of
others.43
In conclusion, our study has confirming the relevance of
oxidative stress and nitrogen species in asbestosis, and
suggests that EBC biomarkers may prove useful non-invasive
tools in diagnosing and distinguishing between the different
asbestos-related disorders in the future.Conflict of interest statements
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